Risk factors associated with multisystem inflamatory syndrome temporally associated with COVID infection in San Rafael hospital.

Main Article Content

Debbie Carolina Raga García
Javier Mauricio Mora Mendez
Arnold Lizardo Camacho Jimenez

Abstract

Background: Multisystemic inflammatory syndrome temporarily associated with COVID infection (SIMS-TAC) is a post-infectious complication of COVID 19, the first cases were reported in 2020, consisting of persistent fever, diffuse inflammation and mucocutaneous manifestations, associated with a history of COVID 19 infection. It frequently generates multiorgan dysfunction with cardiac, renal, hematologic, gastrointestinal manifestations, alterations of the general condition such as hypotension, shock and severe systemic inflammation.   


Objectives: To identify the risk factors associated with the development of SIMS TAC in patients attended at the Hospital Universitario Clínica San Rafael. 


Methods: Case-control study in pediatric patients with SIMS TAC and patients with moderate or  severe COVID 19 infection.


Results: Forty-five patients (15 cases and 30 controls) were included.  Risk factors for developing SIMSTAC were age older than 5 years (OR 14 CI 95% 1.8-103.6 P 0.001) and obesity (OR 0.09 CI95% 0.01-0.94 P 0.036). As a protective factor, co-sleeping was found (OR 9.7 CI 2.2-42.6 P0.002). The other risk factors showed no significant differences. Lymphadenopathy was a relevant finding in the SIMSTAC group (OR 0.29 CI95% 0.18-0.47 P 0.034). The other laboratory and paraclinical differences are expected for the SIMSTAC group of patients. 


Conclutions: The risk factors associated with the development of SIMS TAC were age older than 5 years, overweight or obesity and as a protective factor co-sleeping. The presence of lymphadenopathy should increase the diagnostic suspicion together with the established classificatory criteria.

Downloads

Download data is not yet available.

Article Details

How to Cite
Raga García, D. C., Mora Mendez, J. M., & Camacho Jimenez, A. L. (2024). Risk factors associated with multisystem inflamatory syndrome temporally associated with COVID infection in San Rafael hospital . Pediatría, 57(2), e460. https://doi.org/10.14295/rp.v57i2.460
Section
Originals

References

Mohamed K, Rzymski P, Islam MS, Makuku R, Mushtaq A, Khan A, et al. COVID‐19 vaccinations: The unknowns, challenges, and hopes. J Med Virol. 2022 Apr; 94:1336-49.

https://doi.org/10.1002/jmv.27487.

Nikolopoul G, Maltezou H. COVID-19 in Children: Where do we Stand?. Arch Med Res. 2021; 53: 1-8. https://doi.org/10.1016/j.arcmed.2021.07.002.

Blatz AM, Randolph AG. Severe COVID-19 and Multisystem Inflammatory Syndrome in Children in Children and Adolescents. Crit Care Clin. 2022; 38:571-86. https://doi.org/10.1016/j.ccc.2022.01.005.

Expertos participantes en el desarrollo del consenso. Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID-19 en establecimientos de atención de la salud. Recomendaciones basadas en consenso de expertos e informadas en la evidencia. Infect. 2020; 24:154-85. https://doi.org/10.22354/in.v24i3.852.

Acevedo L, Piñeres-Olave B, Niño-Serna L, Vega L, Gomez I, Chacón S, et al. Mortality and clinical characteristics of multisystem inflammatory syndrome in children (MIS-C) associated with covid-19 in critically ill patients: an observational multicenter study (MISCO study). BMC Pediatr. 2021; 21:516. https://doi.org/10.1186/s12887-021-02974-9

Pérez López P, Carvajal Duque D, Salgado García D, Vega Vega M, Ramos-Castaneda J, Ardila Gómez I, et al. Multisystemic Inflammatory Syndrome in Children From the South of Colombia: One Year of Experience. Front Pediatr. 2022; 10: 838922. https://doi.org/10.3389/fped.2022.838922.

Fortich-González R, Soto-Zárate E, Pérez-Hooker E, Echeverry M, Pinzón-Redondo H. Síndrome infamatorio multisistémico en niños temporalmente asociado a COVID-19 en Cartagena, Colombia. Revista de enfermedades infecciosas en pediatria. 2021; 33: 1852-85.

Levy M, Recher M, Hubert H, Javouhey E, Fléchelles O, Leteurtre S, et al. Multisystem Inflammatory Syndrome in Children by COVID-19 Vaccination Status of Adolescents in France. JAMA. 2022; 327:281-3. https://doi.org/10.1001/jama.2021.23262.

Zambrano L, Newhams M, Olson S, Halasa N, Price A, Boom J, et al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021. Morb Mortal Wkly Rep. 2022; 71:52-8. https://doi.org/10.15585/mmwr.mm7102e1.

Nygaard U, Holm M, Hartling U, Glenthøj J, Schmidt L, Nordly S, et al. Incidence and clinical phenotype of multisystem inflammatory syndrome in children after infection with the SARS-CoV-2 delta variant by vaccination status: a Danish nationwide prospective cohort study. Lancet Child Adolesc Health. 2022; 6: 459-65. https://doi.org/10.1016/S2352-4642(22)00100-6.

Tezer h, Bedi̇r demi̇rdağ t. Novel coronavirus disease (COVID-19) in children. Turk J Med Sci. 2020; 50:592-60. https://doi.org/10.3906/sag-2004-174.

Dionne A, Son M, Randolph A. An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2. Pediatr Infect Dis J. 2022; 41:6-9. https://doi.org/10.1097/INF.0000000000003393.

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.